As we approach the end of the year, we at @GenEndeavor continue to think about the challenges that persist in women's healthcare. Despite some incredible progress made in cancer research, sadly, advanced stage ovarian cancer still results in a 17% survival rate. There are nearly 4 billion women in the world, yet there remains no screening test available. The limitations of current technologies mean that many women continue to face risks undetected until it's too late.
The good news is that more and more, the public is becoming aware of the lack of truly viable solutions. In fact, in October, First Lady Jill Biden announced an important initiative focused on womens’ health research. The announcement underscores the need for collaboration across all stakeholders – biotech firms, research institutes, investors and healthcare providers - to find solutions to the most significant women’s health care conditions and diseases, including ovarian cancer.
As we close the year, I want to share my sincere gratitude to the @NIH for awarding us several grants to accelerate our work in the early detection of genetic and infectious disease and their continued support of GenEndeavor’s technology and mission.
We wish everyone a very healthful and happy new year. #OvarianCancerAwareness #EarlyDetectionMatters #WomenInHealthcare
https://apnews.com/article/jill-biden-research-womens-health-gender-policy-dbe0eec03767cacbbccd07cc83ee15df